TY - JOUR
T1 - Bladder preservation
T2 - Translating discovery for clinical impact in urothelial cancer
AU - Miyamoto, David T.
AU - Abbosh, Philip H.
AU - West, Catharine M.L.
AU - Mouw, Kent W.
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Muscle-invasive bladder cancer can be treated with either radical cystectomy or bladder preservation approaches, and there is a need for reliable biomarkers to guide the optimal choice of therapy. The recent elucidation of the genomic landscape and biological drivers of bladder cancer has enabled the identification of tumor molecular features that may be helpful in driving clinical decision-making. Here, we summarize recent efforts to develop molecular biomarkers that could be leveraged to guide therapeutic decisions, post-treatment monitoring, and the optimal use of bladder preservation approaches for the effective treatment of muscle-invasive bladder cancer.
AB - Muscle-invasive bladder cancer can be treated with either radical cystectomy or bladder preservation approaches, and there is a need for reliable biomarkers to guide the optimal choice of therapy. The recent elucidation of the genomic landscape and biological drivers of bladder cancer has enabled the identification of tumor molecular features that may be helpful in driving clinical decision-making. Here, we summarize recent efforts to develop molecular biomarkers that could be leveraged to guide therapeutic decisions, post-treatment monitoring, and the optimal use of bladder preservation approaches for the effective treatment of muscle-invasive bladder cancer.
KW - Carcinoma, Transitional Cell/surgery
KW - Humans
KW - Organ Sparing Treatments
KW - Urinary Bladder Neoplasms/surgery
UR - http://www.scopus.com/inward/record.url?scp=85097108223&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2020.11.021
DO - 10.1016/j.urolonc.2020.11.021
M3 - Review article
C2 - 33257220
SN - 1078-1439
VL - 39
SP - 201
EP - 208
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 4
ER -